Assessment of oxidative, inflammatory, and fibrinolytic biomarkers and DNA strand breakage in hypercholesterolemia

Inflammation

Volumn 36, Issue 4, 2013, Pages 869-877

  Da Silva Pereira, Renata ^a   Tatsch, Etiane ^a   Bochi, Guilherme Vargas ^a   Kober, Helena ^a   Duarte, Thiago ^a   Dos Santos Montagner, Greice Franciele Feyh ^a   Da Silva, José Edson Paz ^a   Duarte, Marta Maria Medeiros Frescura ^b   Da Cruz, Ivana Beatrice Mânica ^a   Moresco, Rafael Noal ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

advanced oxidation protein products; fibrinolysis; hypercholesterolemia; inflammation; oxidative stress

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; CHOLESTEROL; D DIMER; GLUCOSE; INTERLEUKIN 6; ISCHEMIA MODIFIED ALBUMIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; NITRITE; PROTEIN; THIOL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMET ASSAY; CONTROLLED STUDY; DIET RESTRICTION; DNA STRAND BREAKAGE; FEMALE; FIBRINOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM;

ADVANCED OXIDATION PROTEIN PRODUCTS; BIOLOGICAL MARKERS; BLOOD PROTEINS; DNA BREAKS; FEMALE; FIBRINOLYSIS; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 84880256534     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9614-2     Document Type: Article

References (66)

1. Ghandehari, H.; S. Kamal-Bahl, and N.D. Wong. 2008. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. American Heart Journal 156: 112-119.
2. Tailor, A.; and D.N. Granger. 2003. Hypercholesterolemia promotes P-Selectin-dependent platelet-endothelial cell adhesion in postcapillary venules. Arteriosclerosis, Thrombosis, and Vascular Biology 23: 675-680.
3. Libby, P. 2000. Changing concepts of atherogenesis. Journal of Internal Medicine 247: 349-358.
4. Kotur-Stevuljevic, J.; L. Memon, A. Stefanovic, S. Spasic, V. Spasojevic-Kalimanovska, N. Bogavac-Stanojevic, D. Kalimanovska-Ostric, Z. Jelic-Ivanovic, and G. Zunic. 2007. Correlation of oxidative stress parameters and inflammatory markers in coronary arterydisease patients. Clinical Biochemistry 40: 181-187.
5. Vassalle, C.; L. Pratali, C. Boni, A. Mercuri, and R. Ndreu. 2008. An oxidative stress score as a combined measure of the pro-oxidant and anti-oxidant counterparts in patients with coronary artery disease. Clinical Biochemistry 41: 1162-1167.
6. Marnett, L.J. 2000. Oxyradicals of DNA damage. Carcinogenesis 21(3): 361-370.
7. Olinsky, R.; D. Garckowski, M. Foksinski, R. Rozalski, K. Roszkowski, and P. Jaruga. 2002. Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis, and acquired immunodeficiency syndrome. Free Radical Biology & Medicine 33(2): 192-200.
8. Andreassi, M.G. 2003. Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutation Research 543: 67-86.
9. Botto, N.; A. Rizza, M.G. Colombo, A.M. Mazzone, S. Manfredi, S. Masetti, A. Clerico, A. Biagini, and M.G. Andreassi. 2001. Evidence for DNA damage in patients with coronary artery disease. Mutation Research 493: 23-30.
10. Bar-Or, D.; E. Lau, and J.V. Winkler. 2000. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. The Journal of Emergency Medicine 19: 311-315.
11. Cichota, L.C.; R.N. Moresco, M.M. Duarte, and J.E. Da Silva. 2008. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. Journal of Clinical Laboratory Analysis 22: 1-5.
12. Piva, S.J.; M.M.F. Duarte, I.B.M. Da Cruz, A.C. Coelho, A.P. Moreira, R. Tonello, S.C. Garcia, and R.N. Moresco. 2011. Ischemia-modified albumin as na oxidative stress biomarker in obesity. Clinical Biochemistry 44: 345-347.
13. Kaefer, M.; S.J. Piva, J.A. De Carvalho, D.B. Da Silva, A.M. Becker, A.C. Coelho, M.M. Duarte, and R.N. Moresco. 2010. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clinical Biochemistry 43: 450-454.
14. Gottlieb, M.G.V.; I.B.M. Da Cruz, M.M.F. Duarte, R.N. Moresco, M. Wiehe, C.H. Schwanke, and L.C. Bonadese. 2010. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. Journal of Clinical Endocrinology and Metabolism 95: 586-591.
15. Duarte, M.M.; J.B. Rocha, R.N. Moresco, T. Duarte, I.B.M. Da Cruz, V.L. Loro, and M.R. Schetinger. 2009. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clinical Biochemistry 42: 666-671.
16. Witko-Sarsat, V.; M. Friedlander, C. Capeillère-Blandin, T. Nguyen-Khoa, A.T. Nguyen, J. Zingraff, P. Jungers, and B. Descamps-Latscha. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 49: 1304-1313.
17. Drüeke, T.; V. Witko-Sarsat, Z. Massy, B. Descamps-Latscha, A.P. Guerin, S.J. Marchais, V. Gausson, and G.M. London. 2002. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217.
18. Descamps-Latscha, B.; V. Witko-Sarsat, T. Nguyen-Khoa, A.T. Nguyen, V. Gausson, N. Mothu, G.M. London, and P. Jungers. 2005. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. American Journal of Kidney Diseases 45: 39-47.
19. Nedeljkovic, Z.S.; N. Gokce, and J. Loscalzo. 2003. Mechanisms of oxidative stress and vascular dysfunction. Postgraduate Medical Journal 79: 195-200.
20. Armstrong, E.J.; D.A. Morrow, and M.S. Sabatine. 2006. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation 113: 72-75.
21. Vita, J.A.; C.B. Treasure, E.G. Nabel, J.M. McLenachan, R.D. Fish, A.C. Yeung, V.I. Veksthein, A.P. Selwyn, and P. Ganz. 1990. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81: 491-497.
22. Francisco, G.; C. Hernández, and R. Simó. 2006. Serum markers of vascular inflammation in dyslipemia. Clinica Chimica Acta 369: 1-16.
23. Lowe, G.D.O.; J.W.G. Yarnell, A. Rumley, D. Bainton, and D.M. Sweetnam. 2001. C-reactive protein, fibrin D-dimer and incident ischemic heart disease in the Speedwell Study. Are inflammation and fibrin turnover linked in pathogenesis? Arteriosclerosis, Thrombosis, and Vascular Biology 21: 603-610.
24. Lowe, G.D.O.; A. Rumley, A.D. Mchahon, I. Ford, D.S.J. O'Reilly, and C.J. Packard. 2004. Interleukin-6, fibrin D-dimer, an coagulation factors VII and XIIa in prediction of coronary heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 1529-1524.
25. Sakamotok, K.; Y. Yamamoto, H. Okamatsu, and M. Okabe. 2011. D-dimer is helpful for differentiating acute aortic dissection and acute pulmonary embolism from acute myocardial infarction. Hellenic Journal of Cardiology 52(2): 123-127.
26. Skilton, M.R.; P. Moulin, A. Sérusclat, P. Nony, and F. Bonnet. 2007. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis 190: 416-422.
27. Friedewald, W.T.; R.I. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18: 499-502.
28. Ellman, G.L. 1959. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 82: 70-77.
29. Tatsch, E.; G.V. Bochi, R.S. Pereira, H. Kober, V.A. Agertt, M.M.A. De Campos, P. Gomes, M.M. Duarte, and R.N. Moresco. 2011. A simple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clinical Biochemistry 44: 348-350.
30. Selmeci, L.; L. Seres, M. Antal, J. Lukács, A. Regöly-Méreia, and G. Acsády. 2005. Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: a simple, fast and inexpensive automated technique. Clinical Chemistry and Laboratory Medicine 43: 294-297.
31. McKelvey-Martin, V.J.; M.H. Green, P. Schmezer, B.L. Pool-Zobel, M.P. De Méo, and A. Collins. 1993. The single cell gel electrophoresis assay (comet assay): a European review. Mutation Research 288: 47-63.
32. Singh, N.; M. McCoy, R. Tice, and E. Schneider. 1995. A simple technique for quantification of low levels of DNA damage in individuals cells. Experimental Cell Research 175: 184-191.
33. Tice, R.R.; D. Agurell, D. Anderson, B. Burlinson, A. Hartmann, H. Kobayashi, Y. Miyamae, E. Rojas, J.C. Ryu, and Y.F. Sasaki. 2000. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environmental and Molecular Mutagenesis 35: 206-221.
34. Hartmann, A.; E. Agurell, C. Beevers, S. Brendler-Schwaab, B. Burlinson, P. Clay, A. Collins, G. Smith, G. Speit, V. Thybaud, and R.R. Tice. 2003. Recommendations for conducting the in vivo alkaline comet assay. Mutagenesis 18: 45-51.
35. Nadin, S.; L. Vargas-Roig, and D. Ciocca. 2001. A silver staining method for single-cell gel assay. Journal of Histochemistry and Cytochemistry 49: 1183-1186.
36. Marsche, G.; S. Frank, A. Hrzenjak, M. Holzer, S. Dirnberger, C. Wadsack, H. Scharnagl, T. Stojakovic, A. Heinemann, and K. Oettl. 2009. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circulation Research 104: 750-757.
37. Redón, J.; M.R. Oliva, C. Tormos, V. Giner, J. Chaves, A. Iradi, and G.T. Sáez. 2003. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 41: 1096-1101.
38. Roy, D.; J. Quiles, D.C. Gaze, P. Collinson, J.C. Kaski, and G.F. Baxter. 2006. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 92: 113-114.
39. Roy, D.; and J.C. Kaski. 2007. Ischemia-modified albumin: the importance of oxidative stress. Journal of the American College of Cardiology 49: 2375-2376.
40. Abramson, J.L.; W.C. Hooper, D.P. Jones, S. Ashfaq, S.D. Rhodes, W.S. Weintraub, D.G. Harrisson, A.A. Quyyumi, and V. Vacarinno. 2005. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis 178: 115-121.
41. Aydin, S.; H. Uzun, V. Sozer, and T. Altug. 2009. Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits. Pharmacological Research 59: 242-247.
42. Pandey, K.B.; N. Mishra, and S.I. Rizvi. 2010. Protein oxidation biomarkers in plasma of type 2 diabetic patients. Clinical Biochemistry 43: 508-511.
43. Kelly, C.J.; A. Speirs, G.W. Gould, J.R. Petrie, H. Lyall, and J.M. Connell. 2002. Altered vascular function in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 87: 742-746.
44. Piwowar, A.; M.K. Kordecka, and M. Warwas. 2007. AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 77: 188-192.
45. Kaya, C.; A.F. Erkan, S.D. Cengiz, I. Dünder, O.E. Demirel, and A. Bilgihan. 2009. Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycist ovary syndrome. Fertility and Sterility 92: 1372-1377.
46. Liu, S.X.; F.F. Hou, Z.J. Guo, R. Nagai, W.R. Zhang, Z.Q. Liu, Z.M. Zhou, M. Zhou, D. Xie, G.B. Wang, and X. Zhang. 2006. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 1156-1162.
47. Mercer, J.R.; K.K. Cheng, N. Figg, I. Gorenne, M. Mahmoudi, J. Griffin, and A. Vidal-Puig. 2010. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circulation Research 107: 1021-1031.
48. Harangi, M.; E. Remenyik, I. Seres, Z. Varga, E. Katona, and G. Paragh. 2002. Determination of DNA damage induced by oxidative stress in hyperlipidemic patients. Mutation Research 513: 17-25.
49. Dalboni, S.; B.P. Campagnaro, C.L. Tonin, E.C. Vasquez, and S.S. Meyrelles. 2012. The concurrence of hypercholesterolemia and aging promotes DNA damage in apolipoprotein E-deficient mice. Open Journal of Blood Diseases 2: 51-55.
50. Madamanchi, N.R.; R. Zhou, A.E. Vendrov, X. Niu, and M.S. Runge. 2010. Does oxidative DNA damage cause atherosclerosis and metabolic syndrome? Circulation Research 107: 940-942.
51. Bermudez, E.A.; N. Rifai, J. Buring, J.E. Manson, and P.M. Ridker. 2002. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arteriosclerosis, Thrombosis, and Vascular Biology 22: 1668-1673.
52. Porreca, E.; C. Di Febbo, A. Di Castelnuovo, G. Baccante, C. Amore, A. Angelini, M. Di Nisio, M. Donati, F. Cuccurullo, and L. Iacoviello. 2002. Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients. Atherosclerosis 165: 159-166.
53. Kearon, C.; J.S. Ginsberg, J. Douketis, M. Crowther, P. Brill-Edwards, J.I. Weitz, and J. Hirsh. 2001. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Annals of Internal Medicine 135: 108-111.
54. Moresco, R.N.; L.C.R. Vargas, R. Halla-Junior, and L.M.R. Silla. 2005. Lack of association between cardiac troponin T and D-Dimer in the evaluation of myocardial damage. Journal of Clinical Laboratory Analysis 19: 282-284.
55. Lee, A.J.; F.G. Fowkes, G.D. Lowe, and A. Rumley. 1995. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thrombosis and Haemostasis 74: 828-832.
56. McDermott, M.M.; P. Greenland, D. Green, J.M. Guralnik, M.H. Criqui, K. Liu, C. Chan, W.H. Pearse, L. Taylor, P.M. Ridker, J.R. Schneider, G. Martin, N. Rifai, and M. Quann. 2003. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 107: 3191-3198.
57. Rajavashisth, T.B.; X.P. Xu, S. Jovinge, S. Meisel, X.O. Xu, N.N. Chai, M.C. Fishbein, S. Kaul, B. Cercek, B. Sharifi, and P.K. Shah. 1999. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 99: 3103-3109.
58. Rao, K.M.; C.S. Pieper, M.S. Currie, and H.J. Cohen. 1994. Variability of plasma IL-6 and crosslinked fibrin dimers over time in community dwelling elderly subjects. American Journal of Clinical Pathology 102: 802-805.
59. Harrison, D.G. 1996. Endothelial control of vasomotion and nitric oxide production: a potential target for risk factor management. Cardiology Clinics 14: 1-15.
60. Siekmeier, R.; T. Grammer, and W. März. 2008. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. Journal of Cardiovascular Pharmacology and Therapeutics 13: 279-297.
61. Harrison, D.G. 1997. Cellular and molecular mechanisms of endothelial cell dysfunction. Journal of Clinical Investigation 100: 2153-2157.
62. Sposito, A.C. 2004. Emerging insights into hypertension and dyslipidaemia synergies. European Heart Journal 6(Suppl): G8-G12.
63. Tousoulis, D.; A.M. Kampoliam, C. Tentolouris, N. Papageorgiou, and C. Stefanadis. 2012. The role of nitric oxide on endothelial function. Current Vascular Pharmacology 10: 4-18.
64. Feron, O.; C. Dessy, S. Moniotte, J.P. Desager, and J.L. Balligand. 1999. Hipercholesterolemia decrease nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. Journal of Clinical Investigation 03: 897-905.
65. Stefan, J.; M. Schlaich, M. Langenfeld, H. Weihprecht, G. Schmitz, G. Weidinger, and R.E. Schemieder. 1998. Incresed bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. Circulation 98: 211-216.
66. Rahman, M.M.; Z. Varghese, and J.F. Moorhead. 2001. Paradoxical increase in nitric oxide synthase activity in hypercholesterolaemic rats with impaired renal function and decreased activity of nitric oxide. Nephrology, Dialysis, Transplantation 16: 262-268.